Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Davila

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Transplantation and Cellular Therapy|April 2, 2021
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-AnalysisFarhad Khimani, Mudit Dutta, Rawan Faramand, et al.
Haematologica|January 21, 2017
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantationBrian C Betts, Joseph Pidala, Jongphil Kim, et al.
Transplantation and Cellular Therapy|July 30, 2021
Increased Infections and Delayed CD4<sup>+</sup> T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic TransplantationFarhad Khimani, Peter Ranspach, Hany Elmariah, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphomaEhsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
Haematologica|December 16, 2017
<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantationJoseph Pidala, Francisca Beato, Jongphil Kim, et al.
Blood|July 3, 2020
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomasMargery Gang, Nancy D Marin, Pamela Wong, et al.
Cell|April 12, 2025
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificityTaisuke Kondo, François X P Bourassa, Sooraj Achar, et al.
Cancer Cell|December 12, 2025
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunityYihan Zuo, David J Vohwinkel, Bowen Dong, et al.
Research Square|April 16, 2025
CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphomaMarco Davila, Sae Bom Lee, Yun Pyo Kang, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Transplantation and Cellular Therapy|April 2, 2021
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-AnalysisFarhad Khimani, Mudit Dutta, Rawan Faramand, et al.
Haematologica|January 21, 2017
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantationBrian C Betts, Joseph Pidala, Jongphil Kim, et al.
Transplantation and Cellular Therapy|July 30, 2021
Increased Infections and Delayed CD4<sup>+</sup> T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic TransplantationFarhad Khimani, Peter Ranspach, Hany Elmariah, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphomaEhsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
Haematologica|December 16, 2017
<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantationJoseph Pidala, Francisca Beato, Jongphil Kim, et al.
Blood|July 3, 2020
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomasMargery Gang, Nancy D Marin, Pamela Wong, et al.
Cell|April 12, 2025
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificityTaisuke Kondo, François X P Bourassa, Sooraj Achar, et al.
Cancer Cell|December 12, 2025
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunityYihan Zuo, David J Vohwinkel, Bowen Dong, et al.
Research Square|April 16, 2025
CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphomaMarco Davila, Sae Bom Lee, Yun Pyo Kang, et al.
Pageof 3